View this email in your browser
TrialStat Holiday Newsletter 2020
This holiday season is going to be quite different, much like all of 2020 has been different. This year, we’re staying home, seeing friends and family remotely, and enjoying zoom meetups each month to discuss challenges, share solutions, and stay up to date on the latest clinical research innovations.

Interested in connecting with industry colleagues?

If you’d like to join us in January, or for a future 2021 meeting, please sign up for our "Ask Us Anything Clinical Research” informal networking events here.

We're always looking for guest speakers as well, so reach out if you have knowledge to share!

What's on your solutions road map for 2021?

As the challenges of COVID persist, and disruption to normal clinical trial processes continue, we are seeing increased need from clients for flexible, integrated technology solutions that can be seamlessly adopted within tight timelines.

Key requirements that we are seeing as drivers for new technology investment include:
  • simplifying data entry and reducing the number of vendors/platforms required per study
  • better remote monitoring tools that reduce effort, increase oversight, and identify issues sooner
  • adoption of eConsent and TeleMedicine to broaden potential patient population sizes and increase protocol compliance
  • increasing patient engagement and more accurate remote patient reporting
  • high touch customer support and better quality services with reliable timelines
  • improving data quality and access to custom, up-to-the-minute data analytics for study and risk management without manual reconciliation across multiple platforms
If your current tools are not well positioned to help you succeed in this rapidly changing clinical landscape, we would welcome a conversation about how TrialStat can help solve your most urgent challenges and better support your team through 2021 and beyond. It's easy to book a short conversation, click here to schedule a call.

As we close out 2020, we are thankful to be a part of an industry that is more important now than ever. Thank you for all that you do, and we hope to see more of you in 2021!

Best wishes to you and yours for a safe and happy holiday,
Chris Hamelin
Business Unit Head
TrialStat Solutions, Inc.

Ask Us Anything In Clinical Trials - Holiday Meetup!

On December 16th, Heather Williams and Christopher Kata hosted the final 2020 virtual networking meeting for 2020 in the Ask us Anything in Clinical Research series. Decembers networking meeting  reflected on what has been a very challenging year for clinical research, and what we can look forward to in 2021.

Thank you to everyone who joined - it was wonderful speaking with you all and discussing what will be an exciting 2021!

For those of you who could not attend, you can always watch the recording by clicking the image above, or the button below.

Watch The Recorded Meeting

Discover how TrialStat's eClinical Suite Is Empowering Decentralized Clinical Trials

TrialStat eClnical Suite is designed to run entire clinical programs from feasibility studies, through phase 1, 2 and 3 into post marketing and supports the unique requirements of Oncology Trials, Medical Device and Diagnostic studies. Based on an open platform with powerful API, TrialStat can integrate with EMR / EHR systems for gathering Real World Data while streamlining the data entry process. Capture data from wearable devices, use validated machine learning algorithms, aggregate your medical imaging in our Vendor Neutral Imaging Archive and take advantage of eConsent, Remote Monitoring and TeleMedicine.

Click the button below to explore this interactive diagram of the TrialStat's eClinical Suite.

Discover The Power of TrialStat

Argentina’s IVERCAR Ivermectin & Carrageenan Study Shows Positive Results Targeting COVID-19

Excerpt from the Article:

Based in the southern end of Greater Buenos Aires, Argentina, Eurnekian Public Hospital recently sponsored a clinical trial targeting COVID-19 called the IVERCAR study. The sponsor was joined by other local hospitals acting as trial site organizations. With study results in, the Argentinian group has discovered that while in the control group, 58% of the participants were infected with COVID-19 during the trial, but the intervention arm (carrageenan plus ivermectin) revealed that the compound’s virucidal effects can actually protect patients against SARS-CoV-2 and serve as a sort of prophylaxis. These study results follow up on other positive results out of another randomized controlled study out of Egypt published by TrialSite last week. 

Intervention Combination

This study used a combination of ivermectin (Ivercass) and iota Carrageenan. The hypothesis involving iota carrageenan comes out of a recently published study in preprint server bioRxiv found that the compound typically used as a thickening agent in food products successfully inhibited SARS-CoV-2 in cell cultures at a concentration as low as 6ug/ml.

Click the button below to continue reading the Article:

Read The Article
Additional News Stories
A New Paradigm in Data Management Technology
Learn More About TrialStat
A New Paradigm In Data Management Technology
LinkedIn - TrialStat Solutions Inc.
Copyright © 2020 TrialStat Solutions Inc., All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.